Want to see ELUT full AI Analyst Report?
ELUT Stock Chart & Stats
$0.64
$0.15(4.48%)
At close: 4:00 PM EST
$0.64
$0.15(4.48%)
Day’s Range― - ―
52-Week Range$0.50 - $2.60
Previous CloseN/A
Volume4.31K
Average Volume (3M)364.18K
Market Cap
$42.97M
Enterprise Value$21.43M
Total Cash (Recent Filing)$28.49M
Total Debt (Recent Filing)$4.22M
Price to Earnings (P/E)0.8
Beta0.17
Next Earnings
Aug 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding44,208,237
10 Day Avg. Volume362,745
30 Day Avg. Volume364,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.04
Price to Sales (P/S)2.33
P/FCF Ratio-0.61
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue1.34
Enterprise Value/Gross Profit2.48
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$5.00Price Target Upside681.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$12.00M
Bulls Say, Bears Say
Bulls Say
Market AcceptanceProduct uptake for EluPro is robust, with substantial same-center sales growth and over 100 active accounts, indicating strong market acceptance.
Product PositioningEluPro is positioned as a superior product with antibiotic properties and a soft biomatrix for better patient comfort and pacemaker protection, likely to capture significant market share.
Bears Say
Product PerformanceSimpliDerm was below expectations in Q4 due to partner Tiger working through its reorganization process.
Elutia News
ELUT FAQ
What was Elutia’s price range in the past 12 months?
Elutia lowest stock price was $0.50 and its highest was $2.60 in the past 12 months.
What is Elutia’s market cap?
Elutia’s market cap is $42.97M.
When is Elutia’s upcoming earnings report date?
Elutia’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were Elutia’s earnings last quarter?
Elutia released its earnings results on May 14, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.
Is Elutia overvalued?
According to Wall Street analysts Elutia’s price is currently Undervalued.
Does Elutia pay dividends?
Elutia does not currently pay dividends.
What is Elutia’s EPS estimate?
Elutia’s EPS estimate is -0.15.
How many shares outstanding does Elutia have?
Elutia has 44,208,237 shares outstanding.
What happened to Elutia’s price movement after its last earnings report?
Elutia reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -0.962%.
Which hedge fund is a major shareholder of Elutia?
Currently, no hedge funds are holding shares in ELUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elutia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (681.25% Upside)
$5.00 (681.25% Upside)
Hedge Fund Trend
Increased
By 12.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.17%
12-Months-Change
Fundamentals
Return on Equity
-560.64%
Trailing 12-Months
Asset Growth
40.49%
Trailing 12-Months
Company Description
Elutia
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
ELUT Company Deck
ELUT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful strategic and operational progress: positive regulatory interactions, the automated manufacturing platform coming online with an >80% gross margin target, improved reported gross margins, clear commercial validation and a large $1.5B market opportunity. However, current revenues remain small ($3.1M), one legacy product (SimpliDerm) saw a ~19% decline, operating expenses exceed revenue, and GAAP net loss widened significantly (≈+92%), with continued reliance on strategic transactions and future FDA approvals to de-risk the story. On balance, the forward-looking operational and regulatory advances and the sizable market opportunity outweigh near-term financial shortfalls, but execution and timing risks remain.View all ELUT earnings summariesELUT Stock 12 Month Forecast
Average Price Target
$5.00
▲(681.25% Upside)
Technical Analysis
Ownership Overview
14.31% Insiders
2.88% Mutual Funds
29.49% Other Institutional Investors
50.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---